Patent Claims

1. Bicyclic heterocycles of general formula



, (I)

R_a denotes a hydrogen atom or a methyl group,

R_b denotes a phenyl, benzyl or 1-phenylethyl group, wherein the phenyl core is substituted in each case by the groups R_1 to R_3, whilst

R_1 and R_2, which may be identical or different, each denote a hydrogen, fluorine, chlorine, bromine or iodine atom,

a methyl, ethyl, hydroxy, methoxy, ethoxy, amino, cyano, vinyl or ethynyl group,

an aryl, aryloxy, arylmethyl or arylmethoxy group,

a methyl or methoxy group substituted by 1 to 3 fluorine atoms or

R_1 together with R_2, if they are bound to adjacent carbon atoms, denote a -CH=CH-CH=CH-, -CH=CH-NH- or -CH=N-NH- group and

R_3 denotes a hydrogen, fluorine, chlorine or bromine atom,

R_c denotes a hydrogen atom or a methyl group,

X denotes a methyne group substituted by a cyano group or a nitrogen atom,

A denotes a 1,1- or 1,2-vinylene group, each of which may be substituted by one or two methyl groups or by a trifluoromethyl group,

an ethynylene group, or

a 1,3-butadien-1,4-ylene group optionally substituted by a methyl or trifluoromethyl group,

B denotes a hydrogen atom or a C_{1-4}-alkyl group, a methyl group substituted by 1 to 3 fluorine atoms, an ethyl group substituted by 1 to 5 fluorine atoms, a C_{1-4}-alkylcarbonyl, carboxy, C_{1-4}-alkoxycarbonyl, aminocarbonyl, C_{1-4}-alkylaminocarbonyl, di-(C_{1-4}-alkyl)-aminocarbonyl, pyrrolidinocarbonyl, piperidinocarbonyl, morpholinocarbonyl or a 4-(C_{1-4}-alkyl)-piperazinocarbonyl group, or

a C_{1-4}-alkyl group substituted by the group R_4, whilst

R_4 denotes a C_{1-4}-alkoxy group,

an amino group substituted by two C_{1-4}-alkyl groups, wherein the alkyl groups may be identical or different and each alkyl moiety may be substituted from position 2 by a C_{1-4}-alkoxy- or di-(C_{1-4}-alkyl)-amino group or by a 4- to 7-membered alkyleneimino group, whilst in the above-mentioned 6- to 7-membered alkyleneimino groups in each case a methylene group may be replaced in the 4-position by an oxygen or sulphur atom, by a sulphinyl, sulphonyl or N-(C_{1-4}-alkyl)-imino group,

a 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 methyl groups,

a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups, wherein in each case a methylene group in the 4-position is replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl or N-(C_{1-2}-alkyl)-imino group, or

an imidazolyl group optionally substituted by 1 to 3 methyl groups,

C denotes a C_{1-6}-alkylene group, a -O-C_{1-6}-alkylene group, whilst the alkylene moiety is linked to the group D, or an oxygen atom, which may not be linked to a nitrogen atom of the group D, and

D denotes a pyrrolidino group in which the two hydrogen atoms are replaced in the 2-position by a group E, wherein

E denotes a $-CH_2-O-CO-CH_2-$, $-CH_2CH_2-O-CO-$, $-CH_2-O-CO-CH_2CH_2-$, $-CH_2CH_2-O-CO-CH_2-$ or $-CH_2CH_2CH_2-O-CO-$ bridge optionally substituted by one or two C_{1-2}-alkyl groups,

a pyrrolidino group in which the two hydrogen atoms are replaced in the 3-position by a group F, wherein

F denotes a $-O-CO-CH_2CH_2-$, $-CH_2-O-CO-CH_2-$, $-CH_2CH_2-O-CO-$, $-O-CO-CH_2CH_2CH_2-$, $-CH_2-O-CO-CH_2CH_2-$, $-CH_2CH_2-O-CO-CH_2-$, $-CH_2CH_2CH_2-O-CO-$, $-O-CO-CH_2-NR_5-CH_2-$, $-CH_2-O-CO-CH_2-NR_5-$, $-O-CO-CH_2-O-CH_2-$ or $-CH_2-O-CO-CH_2-O-$ bridge optionally substituted by one or two C_{1-2}-alkyl groups, whilst

R_5 denotes a hydrogen atom or a C_{1-4}-alkyl group,

a piperidino or hexahydroazepino group, wherein the two hydrogen atoms are replaced in the 2-position by a group E, where E is as hereinbefore defined,

a piperidino or hexahydroazepino group, wherein in each case the two hydrogen atoms in the 3-position or in the 4-position are replaced by a group F, where F is as hereinbefore defined,

a piperazino- or 4-(C_{1-4}-alkyl)-piperazino group, wherein the two hydrogen atoms in the 2-position or in the 3-position of the piperazino ring are replaced by a group E, where E is as hereinbefore defined,

a pyrrolidino or piperidino group, wherein two vicinal hydrogen atoms are replaced by a -O-CO-CH_2- -CH_2-O-CO-, -O-CO-CH_2CH_2-, -CH_2-O-CO-CH_2-, -CH_2CH_2-O-CO-, -O-CO-CH_2-NR_5- or -O-CO-CH_2-O- bridge optionally substituted by one or two C_{1-2}-alkyl groups, whilst R_5 is as hereinbefore defined and the heteroatoms of the above-mentioned bridges are not bound to the 2- or 5-position of the pyrrolidino ring and are not bound to the 2- or 6-position of the piperidino ring,

a piperazino or 4-(C_{1-4}-alkyl)-piperazino group, wherein a hydrogen atom in the 2-position together with a hydrogen atom in the 3-position of the piperazino ring are replaced by a -CH_2-O-CO-CH_2- or -CH_2CH_2-O-CO- bridge optionally substituted by one or two C_{1-2}-alkyl groups,

a piperazino group in which a hydrogen atom in the 3-position together with the hydrogen atom in the 4-position are replaced by a -CO-O-CH_2CH_2- or -CH_2-O-CO-CH_2- bridge optionally substituted by one or two C_{1-2}-alkyl groups, whilst in each case the left-hand end of the above-mentioned bridges is bound to the 3-position of the piperazino ring,

a pyrrolidino, piperidino or hexahydroazepino group substituted by the group R_6, wherein

R_6 denotes a 2-oxo-tetrahydrofuranyl, 2-oxo-tetrahydropyranyl, 2-oxo-1,4-dioxanyl or 2-oxo-4-(C_{1-4}-alkyl)-

morpholinyl group optionally substituted by one or two C_{1-2}-alkyl groups,

a pyrrolidino group substituted in the 3-position by a 2-oxo-morpholino group, whilst the 2-oxo-morpholino group may be substituted by one or two C_{1-2}-alkyl groups,

a piperidino or hexahydroazepino group substituted in the 3- or 4-position by a 2-oxo-morpholino group, whilst the 2-oxo-morpholino group may be substituted by one or two C_{1-2}-alkyl groups,

a 4-(C_{1-4}-alkyl)-piperazino or 4-(C_{1-4}-alkyl)-homopiperazino group substituted at a ring nitrogen atom by R_6, wherein R_6 is as hereinbefore defined,

a piperazino or homopiperazino group substituted in the 4-position by the group R_7, wherein

R_7 denotes a 2-oxo-tetrahydrofuran-3-yl, 2-oxo-tetrahydrofuran-4-yl, 2-oxo-tetrahydropyran-3-yl, 2-oxo-tetrahydropyran-4-yl or 2-oxo-tetrahydropyran-5-yl group optionally substituted by one or two C_{1-2}-alkyl groups,

a pyrrolidino group substituted in the 3-position by a (R_5NR_7)-, R_7O-, R_7S-, R_7SO- or R_7SO_2- group, whilst R_5 and R_7 are as hereinbefore defined,

a piperidino or hexahydroazepino group substituted in the 3- or 4-position by a (R_5NR_7)-, R_7O-, R_7S-, R_7SO- or R_7SO_2- group, wherein R_5 and R_7 are as hereinbefore defined,

a pyrrolidino, piperidino or hexahydroazepino group substituted by a R_6-C_{1-4}-alkyl-, (R_5NR_7)-C_{1-4}-alkyl-, R_7O-C_{1-4}-alkyl-, R_7S-C_{1-4}-alkyl-, R_7SO-C_{1-4}-alkyl-, R_7SO_2-C_{1-4}-alkyl- or (R_5NR_7)-CO- group, wherein R_5 to R_7 are as hereinbefore defined,

a pyrrolidino group substituted in the 3-position by a R_6-CO-NR_4, R_6-C_{1-4}-alkylene-$CONR_4$, (R_5NR_7)-C_{1-4}-alkylene-$CONR_5$, R_7O-C_{1-4}-alkylene-$CONR_5$, R_7S-C_{1-4}-alkylene-$CONR_5$, R_7SO-C_{1-4}-alkylene-$CONR_5$, R_7SO_2-C_{1-4}-alkylene-$CONR_5$, 2-oxo-morpholino-C_{1-4}-alkylene-$CONR_5$, R_6-C_{1-4}-alkylene-Y or C_{2-4}-alkyl-Y group, whilst the C_{2-4}-alkyl moiety of the C_{2-4}-alkyl-Y group is substituted in each case from position 2 by a (R_5NR_7)-, R_7O-, R_7S-, R_7SO- or R_7SO_2- group and the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups, wherein

R_5 to R_7 are as hereinbefore defined and

Y denotes an oxygen or sulphur atom, an imino, N-(C_{1-4}-alkyl)-imino, sulphinyl or sulphonyl group,

a piperidino- or hexahydroazepino group substituted in the 3- or 4-position by a R_6-CO-NR_5, R_6-C_{1-4}-alkylene-$CONR_5$, (R_5NR_7)-C_{1-4}-alkylene-$CONR_5$, R_7O-C_{1-4}-alkylene-$CONR_5$, R_7S-C_{1-4}-alkylene-$CONR_5$, R_7SO-C_{1-4}-alkylene-$CONR_5$, R_7SO_2-C_{1-4}-alkylene-$CONR_5$, 2-oxo-morpholino-C_{1-4}-alkylene-$CONR_5$, R_6-C_{1-4}-alkylene-Y or C_{2-4}-alkyl-Y group, wherein Y is as hereinbefore defined, the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups and the C_{2-4}-alkyl moiety of the C_{2-4}-alkyl-Y group is substituted in each case from position 2 by a (R_5NR_7)-, R_7O-, R_7S-, R_7SO- or R_7SO_2- group, whilst R_5 to R_7 are as hereinbefore defined,

a 4-(C_{1-4}-alkyl)-piperazino or 4-(C_{1-4}-alkyl)-homopiperazino group substituted at a ring nitrogen atom by a R_6-C_{1-4}-alkyl-, (R_5NR_7)-C_{1-4}-alkyl-, R_7O-C_{1-4}-alkyl-, R_7S-C_{1-4}-alkyl-, R_7SO-C_{1-4}-alkyl-, R_7SO_2-C_{1-4}-alkyl- or R_5NR_7-CO- group, wherein R_5 to R_7 are as hereinbefore defined,

a piperazino or homopiperazino group substituted in the 4-position by a R_6-C_{1-4}-alkyl-, R_6-CO-, R_6-C_{1-4}-alkylene-CO-, (R_5NR_7)-C_{1-4}-alkylene-CO-, R_7O-C_{1-4}-alkylene-CO-, R_7S-C_{1-4}-alkylene-

CO-, R_7SO-C_{1-4}-alkylene-CO- or R_7SO_2-C_{1-4}-alkylene-CO- group, wherein R_5 to R_7 are as hereinbefore defined,

a piperazino or homopiperazino group substituted in the 4-position by a C_{2-4}-alkyl group, wherein the C_{2-4}-alkyl group is substituted in each case from position 2 by an (R_5NR_7)-, R_7O-, R_7S-, R_7SO- or R_7SO_2- group, whilst R_5 and R_7 are as hereinbefore defined,

a pyrrolidino, piperidino- or hexahydroazepino group substituted by a 2-oxo-morpholino-C_{1-4}-alkyl group, wherein the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups,

a pyrrolidino group, substituted in the 3-position by a C_{2-4}-alkyl-Y group, wherein Y is as hereinbefore defined and the C_{2-4}-alkyl moiety of the C_{2-4}-alkyl-Y group is substituted in each case from position 2 by a 2-oxo-morpholino group optionally substituted by one or two C_{1-2}-alkyl groups,

a piperidino or hexahydroazepino group substituted in the 3- or 4-position by a C_{2-4}-alkyl-Y group, wherein Y is as hereinbefore defined and the C_{2-4}-alkyl moiety of the C_{2-4}-alkyl-Y group is substituted in each case from position 2 by a 2-oxo-morpholino group optionally substituted by one or two C_{1-2}-alkyl groups,

a 4-(C_{1-4}-alkyl)-piperazino- or 4-(C_{1-4}-alkyl)-homopiperazino group substituted at a ring nitrogen atom by a 2-oxo-morpholino-C_{1-4}-alkyl group, wherein the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups,

a piperazino or homopiperazino group substituted in the 4-position by a 2-oxo-morpholino-C_{1-4}-alkylene-CO group, wherein the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups,

a piperazino or homopiperazino group substituted in the 4-position by a C_{2-4}-alkyl group, wherein the C_{2-4}-alkyl moiety is substituted in each case from position 2 by a 2-oxo-morpholino group optionally substituted by one or two C_{1-2}-alkyl groups,

a pyrrolidinyl or piperidinyl group substituted in the 1-position by the group R_7, by a R_6-C_{1-4}-alkyl-, R_6-CO-, R_6-C_{1-4}-alkylene-CO-, (R_5NR_7)-C_{1-4}-alkylene-CO-, R_7O-C_{1-4}-alkylene-CO-, R_7S-C_{1-4}-alkylene-CO-, R_7SO-C_{1-4}-alkylene-CO-, R_7SO_2-C_{1-4}-alkylene-CO- or 2-oxo-morpholino-C_{1-4}-alkylene-CO- group, wherein R_5 to R_7 are as hereinbefore defined and the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups,

a pyrrolidinyl or piperidinyl group substituted in the 1-position by a C_{2-4}-alkyl group, wherein the C_{2-4}-alkyl moiety is substituted in each case from position 2 by a (R_5NR_7)-, R_7O-, R_7S-, R_7SO-, R_7SO_2- or 2-oxo-morpholino group, whilst R_5 and R_7 are as hereinbefore defined and the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups,

a pyrrolidin-3-yl-NR_5, piperidin-3-yl-NR_5 or piperidin-4-yl-NR_5 group substituted at the ring nitrogen atom in each case by the group R_7, by a R_6-C_{1-4}-alkyl-, R_6-CO-, R_6-C_{1-4}-alkylene-CO-, (R_5NR_7)-C_{1-4}-alkylene-CO-, R_7O-C_{1-4}-alkylene-CO-, R_7S-C_{1-4}-alkylene-CO-, R_7SO-C_{1-4}-alkylene-CO-, R_7SO_2-C_{1-4}-alkylene-CO- or 2-oxo-morpholino-C_{1-4}-alkylene-CO- group, wherein R_5 to R_7 are as hereinbefore defined and the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups,

a pyrrolidin-3-yl-NR_5, piperidin-3-yl-NR_5 or piperidin-4-yl-NR_5 group substituted in each case at the ring nitrogen atom by a C_{2-4}-alkyl group, wherein the C_{2-4}-alkyl moiety is substituted in each case from position 2 by a (R_5NR_7)-, R_7O-, R_7S-, R_7SO-, R_7SO_2- or 2-oxo-morpholino group, whilst R_5 and R_7 are as hereinbefore defined and the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups,

a R_6-C_{1-4}-alkylene-NR_5 group in which R_5 and R_6 are as hereinbefore defined, or

a C_{2-4}-alkyl-NR_4 group, wherein the C_{2-4}-alkyl moiety is substituted in each case from position 2 by a (R_5NR_7)-, R_7O-, R_7S-, R_7SO-, R_7SO_2- or 2-oxo-morpholino group, whilst R_5 and R_7 are as hereinbefore defined and the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups,

a 2-oxo-morpholin-4-yl group substituted by the group R_8 or by the group R_8 and a C_{1-4}-alkyl group, whilst

R_8 denotes a C_{3-4}-alkyl, hydroxy-C_{1-4}-alkyl, C_{1-4}-alkoxy-C_{1-4}-alkyl, di-(C_{1-4}-alkyl)-amino-C_{1-4}-alkyl, pyrrolidino-C_{1-4}-alkyl, piperidino-C_{1-4}-alkyl, morpholino-C_{1-4}-alkyl, 4-(C_{1-4}-alkyl)-piperazino-C_{1-4}-alkyl, C_{1-4}-alkylsulphanyl-C_{1-4}-alkyl, C_{1-4}-alkylsulphinyl-C_{1-4}-alkyl, C_{1-4}-alkylsulphonyl-C_{1-4}-alkyl, cyan-C_{1-4}-alkyl, C_{1-4}-alkoxycarbonyl-C_{1-4}-alkyl, aminocarbonyl-C_{1-4}-alkyl, C_{1-4}-alkyl-aminocarbonyl-C_{1-4}-alkyl, di-(C_{1-4}-alkyl)-aminocarbonyl-C_{1-4}-alkyl, pyrrolidino-carbonyl-C_{1-4}-alkyl, piperidinocarbonyl-C_{1-4}-alkyl, morpholinocarbonyl-C_{1-4}-alkyl or a 4-(C_{1-4}-alkyl)-piperazino-carbonyl-C_{1-4}-alkyl group,

a 2-oxo-morpholin-4-yl group substituted by two groups R_8, whilst R_8 is as hereinbefore defined and the two groups R_8 may be identical or different,

a 2-oxo-morpholin-4-yl group in which the two hydrogen atoms of a methylene group are replaced by a $-(CH_2)_m$-, $-CH_2-Y-CH_2$-, $-CH_2-Y-CH_2-CH_2$-, $-CH_2CH_2-Y-CH_2CH_2$- or $-CH_2CH_2-Y-CH_2CH_2CH_2$- bridge optionally substituted by one or two C_{1-2}-alkyl groups, whilst

m denotes the number 2, 3, 4, 5 or 6 and
Y denotes an oxygen or sulphur atom, a sulphinyl, sulphonyl or C_{1-4}-alkylimino group,

a 2-oxo-morpholin-4-yl group in which a hydrogen atom in the 5-position together with a hydrogen atom in the 6-position is replaced by a $-(CH_2)_n-$, $-CH_2-Y-CH_2-$, $-CH_2-Y-CH_2CH_2-$ or $-CH_2-CH_2-Y-CH_2-$ bridge, whilst

Y is as hereinbefore defined and
n denotes the number 2, 3 or 4,

whilst, unless otherwise stated, the aryl moieties mentioned in the definitions of the above-mentioned groups denote a phenyl group which may be mono- or disubstituted by R_9, whilst the substituents may be identical or different and

R_9 denotes a fluorine, chlorine, bromine or iodine atom, a C_{1-2}-alkyl, trifluoromethyl or C_{1-2}-alkoxy group, or

two groups R_9, if they are bound to adjacent carbon atoms, together denote a C_{3-4}-alkylene, methylenedioxy or 1,3-butadien-1,4-ylene group,

the tautomers, stereoisomers and the salts thereof.

2. Bicyclic heterocycles of general formula I according to claim 1, wherein

R_a denotes a hydrogen atom,

R_b denotes a 1-phenylethyl, 3-methylphenyl, 3-chlorophenyl, 3-bromophenyl or 3-chloro-4-fluorophenyl group,

R_c denotes a hydrogen atom,

X denotes a nitrogen atom,

A denotes a 1,2-vinylene or ethynylene group,

B denotes a hydrogen atom,

C denotes a $-O-CH_2CH_2-$ or $-O-CH_2CH_2CH_2-$ group, whilst the alkylene moiety in each case is linked to the group D, and

D denotes a piperidino group in which the two hydrogen atoms in the 4-position are replaced by a $-CH_2-O-CO-CH_2$, $-CH_2CH_2-O-CO-$, $-CH_2CH_2-O-CO-CH_2-$, $-O-CO-CH_2-NCH_3-CH_2-$ or $-O-CO-CH_2-O-CH_2-$ bridge,

a piperazino group in which a hydrogen atom in the 3-position together with the hydrogen atom in the 4-position are replaced by a $-CO-O-CH_2-CH_2-$ or $-CH_2-O-CO-CH_2-$ bridge, whilst in each case the left-hand ends of the above-mentioned bridges are bound to the 3-position of the piperazino ring,

a piperidino group which is substituted in the 4-position by a 2-oxo-morpholino or 2-oxo-morpholinomethyl group, whilst the 2-oxo-morpholino moiety may be substituted in each case by one or two methyl groups,

a piperazino group which is substituted in the 4-position by a 2-oxo-tetrahydrofuran-3-yl- or 2-oxo-tetrahydrofuran-4-yl group,

a piperidino group which is substituted in the 4-position by a R_6S group, whilst

R_6 denotes a 2-oxo-tetrahydrofuran-3-yl or 2-oxo-tetrahydrofuran-4-yl group,

a piperazino group which is substituted in the 4-position by a 2-oxo-tetrahydrofuranylmethyl or 2-oxo-tetrahydrofuranylcarbonyl group,

a piperazino group which is substituted in the 4-position by a [2-(2-oxo-tetrahydrofuran-3-ylsulphenyl)ethyl] group,

a piperidin-4-yl group which is substituted in the 1-position by a 2-oxo-tetrahydrofuran-3-yl or 2-oxo-tetrahydrofuran-4-yl group,

a 2-oxo-morpholin-4-yl group which is substituted by a methoxymethyl or methoxyethyl group,

a 2-oxo-morpholin-4-yl group in which the two hydrogen atoms of a methylene group are replaced by a $-CH_2CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2CH_2-$, $-CH_2-O-CH_2CH_2-$ or $-CH_2CH_2-O-CH_2CH_2-$ bridge,

the tautomers, stereoisomers and the salts thereof.

3. Bicyclic heterocycles of general formula I according to claim 1, wherein

R_a denotes a hydrogen atom,

R_b denotes a 1-phenylethyl or 3-chloro-4-fluorophenyl group,

R_c denotes a hydrogen atom,

X denotes a nitrogen atom,

A denotes a 1,2-vinylene group,

B denotes a hydrogen atom,

C denotes a $-O-CH_2CH_2-$ or $-O-CH_2CH_2CH_2-$ group, whilst the alkylene moiety in each case is linked to the group D, and

D denotes a piperazino group which is substituted in the 4-position by a 2-oxo-tetrahydrofuran-4-yl or 2-oxo-tetrahydrofuran-5-ylcarbonyl group,

the tautomers, stereoisomers and the salts thereof.

4. The following compounds of general formula I according to claim 1:

(1) 4-[(3-chloro-4-fluorophenyl)amino]-7-{3-[4-(2-oxo-tetrahydrofuran-4-yl)-piperazin-1-yl]-propyloxy}-6-[(vinylcarbonyl)-amino]-quinazoline,

(2) 4-[(3-chloro-4-fluorophenyl)amino]-7-(2-{4-[(*S*)-(2-oxo-tetrahydrofuran-5-yl)carbonyl]-piperazin-1-yl}-ethoxy)-6-[(vinylcarbonyl)amino]-quinazoline,

(3) 4-[(*R*)-(1-phenylethyl)amino]-7-{2-[4-(2-oxo-tetrahydrofuran-4-yl)-piperazin-1-yl]-ethoxy}-6-[(vinylcarbonyl)amino]-quinazoline and

(4) 4-[(3-chloro-4-fluorophenyl)amino]-7-{2-[4-(2-oxo-tetrahydrofuran-4-yl)-piperazin-1-yl]-ethoxy}-6-[(vinylcarbonyl)-amino]-quinazoline,

the tautomers, stereoisomers and the salts thereof.

5. Physiologically acceptable salts of the compounds according to at least one of claims 1 to 4 with inorganic or organic acids or bases.

6. Pharmaceutical compositions containing a compound according to at least one of claims 1 to 4 or a physiologically acceptable salt according to claim 5 optionally together with one or more inert carriers and/or diluents.

7. Use of a compound according to at least one of claims 1 to 5 for preparing a pharmaceutical composition which is suitable for the treatment of benign or malignant tumours, for preventing and treating diseases of the respiratory tract and lungs, for treating polyps, diseases of the gastro-intestinal

tract, bile duct and gall bladder as well as the kidneys and skin.

8. Process for preparing a pharmaceutical composition according to claim 6, characterised in that a compound according to at least one of claims 1 to 5 is incorporated in one or more inert carriers and/or diluents by a non-chemical method.

9. Process for preparing the compounds of general formula I according to at least one of claims 1 to 5, characterised in that

a) a compound of general formula



, (II)

wherein
R_a to R_c, C, D and X are defined as in claims 1 to 4,
is reacted with a compound of general formula

$$Z_1 - CO - A - B \qquad , (III)$$

wherein
A and B are defined as in claims 1 to 4 and
Z_1 denotes a leaving group, and

if necessary any protecting group used in the reactions described above is cleaved again and/or

if desired a compound of general formula I thus obtained is resolved into its stereoisomers and/or

a compound of general formula I thus obtained is converted into the salts thereof, particularly, for pharmaceutical use, into the physiologically acceptable salts thereof.